New High Precision Kits Available for Gyros Immunoassay Platform

By LabMedica International staff writers
Posted on 31 Mar 2014
New ready-to-use kits designed for the Gyros high-throughput immunoassay platform will enable generation of high quality data for clinical research and drug development faster than typical ELISA kits.

EMD Millipore, life sciences division of Merck KGaA (Darmstadt, Germany) has released its initial set of "GyroMark HT" immunoassay kits, 5 new kits designed specifically for use on the "Gyrolab xP" workstation from Gyros AB (Uppsala, Sweden). Traditional ELISAs can consume significant time, sample, and reagents. With the automated, walk-away system from Gyros, up to 480 data points can be generated in a single run using less sample and reagents. The initial launch includes assays for important metabolic and toxicity biomarkers, such as GLP-1, insulin, clusterin, and KIM-1. EMD Millipore plans to release additional kits this year and offers custom kits for companies with specific needs or unique or novel antibodies.

Caption: EMD Millipore's new high-precision GyroMark HT immunoassays of important biomarkers for use on the Gyros automated, high-throughput platform (Image courtesy of EMD Millipore and Gyros).

The GyroMark HT kits are fully qualified for reliable use in clinical research and feature simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample – with assay precision and accuracy that meet or exceed ELISA performance. “We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” said Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

Employing microfluidic technology with parallel processing, the Gyros platform offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays further provide: accuracy over a four-log dynamic range (compared to two logs for ELISAs); elimination of cross-talk and plate position artifacts; and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Maria Hjortsmark, Gyros’ Global Marketing Director, commented, “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale, and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits to further reduce time-to-results, freeing up analyst time and offering an easier route to robust, reproducible data.”

Related Links:

Gyros
EMD Millipore



Latest Immunology News